Literature DB >> 8270603

Inhibitory effects by oral administration of ginsenoside Rh2 on the growth of human ovarian cancer cells in nude mice.

T Tode1, Y Kikuchi, T Kita, J Hirata, E Imaizumi, I Nagata.   

Abstract

Recently two new compounds, ginsenosides Rh1 and Rh2, have been isolated from an ethanol extract of the processed root of Panax ginseng CA Meyer, and Rh2 (but not Rh1) has been found to cause growth inhibition of cultured B16 melanoma cells. We have also demonstrated that Rh2 caused inhibition of cultured human ovarian cancer cell (HRA) proliferation. The effect of oral administration of Rh2 on tumor growth and survival of nude mice bearing HRA cells was examined. Nude mice were inoculated subcutaneously in the right flank with 10(6) HRA cells. After 7 days of tumor inoculation 2 mg/kg cis-diamminedichloroplatinum(II) (cisplatin) was administered intraperitoneally once a week for 5 weeks. In Rh2-treated groups. Rh2 was dissolved in absolute ethanol, adjusted with distilled water to 1, 15, and 120 microM, and 0.4 ml of each concentration was administered orally by canula every day for 90 days, from the next day of tumor inoculation. The tumor volume, hematocrit and body weight were measured every week. On days 56 and 63 after tumor inoculation, the tumor volumes in all groups treated with Rh2 were significantly less than those in an ethanol-treated control group and also in cisplatin treated group. After 70 days, the tumor growth in nude mice treated with 15 microM and 120 microM Rh2 was significantly inhibited compared to that in a cisplatin treated group as well as a control group. Consequently, the survival of nude mice treated with 15 microM and 120 microM Rh2 was also significantly prolonged, compared to that of cisplatin treated mice. No toxic effects were observed in any of the mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8270603     DOI: 10.1007/bf01200720

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  7 in total

1.  Induction of phenotypic reverse transformation by ginsenosides in cultured Morris hepatoma cells.

Authors:  S Odashima; Y Nakayabu; N Honjo; H Abe; S Arichi
Journal:  Eur J Cancer       Date:  1979-06       Impact factor: 9.162

2.  Determination of panaxytriol, a new type of tumour growth inhibitor from Panax ginseng, by capillary gas chromatography.

Authors:  H Matsunaga; M Katano; H Yamamoto; M Mori; K Takata; M Nishi
Journal:  J Chromatogr       Date:  1989-11-03

3.  Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation.

Authors:  Y Kikuchi; I Kizawa; K Oomori; M Miyauchi; T Kita; M Sugita; Y Tenjin; K Kato
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

4.  Plant-glycoside modulation of cell surface related to control of differentiation in cultured B16 melanoma cells.

Authors:  T Ota; K Fujikawa-yamamoto; Z P Zong; M Yamazaki; S Odashima; I Kitagawa; H Abe; S Arichi
Journal:  Cancer Res       Date:  1987-07-15       Impact factor: 12.701

5.  Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivo.

Authors:  Y Kikuchi; H Sasa; T Kita; J Hirata; T Tode; I Nagata
Journal:  Anticancer Drugs       Date:  1991-02       Impact factor: 2.248

6.  Control of phenotypic expression of cultured B16 melanoma cells by plant glycosides.

Authors:  S Odashima; T Ohta; H Kohno; T Matsuda; I Kitagawa; H Abe; S Arichi
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

7.  Mechanism of action of ginsenoside Rh2: uptake and metabolism of ginsenoside Rh2 by cultured B16 melanoma cells.

Authors:  T Ota; M Maeda; S Odashima
Journal:  J Pharm Sci       Date:  1991-12       Impact factor: 3.534

  7 in total
  18 in total

1.  Ginsenoside Rh2 inhibits metastasis of glioblastoma multiforme through Akt-regulated MMP13.

Authors:  Ning Guan; Xiaochuan Huo; Zhenxing Zhang; Shoudan Zhang; Junsheng Luo; Wenshi Guo
Journal:  Tumour Biol       Date:  2015-04-03

2.  Induction of apoptosis by the ginsenoside Rh2 by internalization of lipid rafts and caveolae and inactivation of Akt.

Authors:  E-K Park; E J Lee; S-H Lee; K H Koo; J Y Sung; E H Hwang; J H Park; C-W Kim; K-C Jeong; B-K Park; Y-N Kim
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

3.  Ginsenoside Rh2 inhibits prostate cancer cell growth through suppression of microRNA-4295 that activates CDKN1A.

Authors:  Qiruo Gao; Junhua Zheng
Journal:  Cell Prolif       Date:  2018-02-19       Impact factor: 6.831

4.  Ginsenoside Rh2 inhibits growth of glioblastoma multiforme through mTor.

Authors:  Shaoyi Li; Wenchang Guo; Yun Gao; Yunhui Liu
Journal:  Tumour Biol       Date:  2014-11-28

5.  Inhibition of prostatic cancer growth by ginsenoside Rh2.

Authors:  Qingchuan Zhang; Bin Hong; Songhua Wu; Tianli Niu
Journal:  Tumour Biol       Date:  2014-11-23

6.  EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2.

Authors:  Shaoyi Li; Yun Gao; Weining Ma; Wenchang Guo; Gang Zhou; Tianci Cheng; Yunhui Liu
Journal:  Tumour Biol       Date:  2014-02-21

7.  Ginsenoside Rh2 alleviates tumor-associated depression in a mouse model of colorectal carcinoma.

Authors:  Jia Wang; Yueming Chen; Chunxiao Dai; Yushan Shang; Jian Xie
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

8.  Ginsenoside Rh2 inhibits invasiveness of glioblastoma through modulation of VEGF-A.

Authors:  Shaoyi Li; Yun Gao; Weining Ma; Tianci Cheng; Yunhui Liu
Journal:  Tumour Biol       Date:  2015-07-29

9.  Ginsenoside Rp1 Exerts Anti-inflammatory Effects via Activation of Dendritic Cells and Regulatory T Cells.

Authors:  Jingyu Bae; Jihye Koo; Soochan Kim; Tae-Yoon Park; Mi-Yeon Kim
Journal:  J Ginseng Res       Date:  2012-10       Impact factor: 6.060

10.  Ginsenosides are novel naturally-occurring aryl hydrocarbon receptor ligands.

Authors:  Qin Hu; Guochun He; Jing Zhao; Anatoly Soshilov; Michael S Denison; Aiqian Zhang; Huijun Yin; Domenico Fraccalvieri; Laura Bonati; Qunhui Xie; Bin Zhao
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.